After plugging billions into its manufacturing network to meet rampant demand for Mounjaro and Zepbound, Eli Lilly is looking ...

Eli Lilly is joining in a lawsuit filed by the Outsourcing Facilities against the FDA, aiming to reverse the FDA's October 2024 determination that the shortage has been resolved, which would allow ...

Eli Lilly moves to defend FDA's tirzepatide shortage resolution amid criticism over supply issues and compounding pharmacy claims.

Eli Lilly and Company (NYSE:LLY – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the ...

Eli Lilly's biggest catalyst at the moment comes from its hit weight loss medications, Mounjaro and Zepbound. Lilly is ...

and online pharmacies have seen a shift to Mounjaro prescriptions. Ro, a telehealth company, has teamed up with Eli Lilly to improve patient access to Zepbound (tirzepatide). Through LillyDirect ...

The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved ...

Shares of Eli Lilly and Company (NYSE:LLY – Get Free Report) dropped 0.6% on Tuesday . The company traded as low as $767.25 and last traded at $768.83. Approximately 348,052 shares traded hands during ...

Eli Lilly's stock has been a strong winner over the past few years, powered by its portfolio of glucagon-like peptide-1 ...

Eli Lilly and Company (NYSE: LLY ... Weekly tirzepatide (Zepbound® and Mounjaro®) injections (pooled 5 mg, 10 mg, 15 mg doses) significantly reduced the risk of progression to type 2 diabetes ...

Eli Lilly is planning to introduce Tirzepatide (or Mounjaro), the company’s diabetes and obesity drug, to the Indian market next year. The company has already received marketing authorization ...

Eli Lilly's GLP-1 drugs, meanwhile, have been powering the company's results. Last quarter, Mounjaro revenue more than doubled year over year to $3.11 billion, while Zepbound added an additional $ ...